An international, randomised, double blind, placebo controlled, parallel group study to investigate whether TroVax [MVA 5T4], added to first-line standard of care therapy, prolongs the survival of patients with locally advanced or metastatic clear cell renal adenocarcinoma.

Trial Profile

An international, randomised, double blind, placebo controlled, parallel group study to investigate whether TroVax [MVA 5T4], added to first-line standard of care therapy, prolongs the survival of patients with locally advanced or metastatic clear cell renal adenocarcinoma.

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Apr 2016

At a glance

  • Drugs MVA 5T4 (Primary)
  • Indications Renal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms TRIST
  • Sponsors Oxford BioMedica
  • Most Recent Events

    • 15 Mar 2011 Results following a further analysis of trial data have been reported in an Oxford BioMedica media release.
    • 29 Sep 2010 Primary endpoint 'Overall survival duration' has not been met.
    • 29 Sep 2010 Results reported in Clinical Cancer Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top